DE69332541T2 - Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie - Google Patents

Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie

Info

Publication number
DE69332541T2
DE69332541T2 DE69332541T DE69332541T DE69332541T2 DE 69332541 T2 DE69332541 T2 DE 69332541T2 DE 69332541 T DE69332541 T DE 69332541T DE 69332541 T DE69332541 T DE 69332541T DE 69332541 T2 DE69332541 T2 DE 69332541T2
Authority
DE
Germany
Prior art keywords
pct
thrombozythemia
hemorrhagic
consuming
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332541T
Other languages
English (en)
Other versions
DE69332541D1 (de
Inventor
Jean-Claude Mestries
Francis Herodin
Serge Martin
Armaud Ythier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929214489A external-priority patent/GB9214489D0/en
Priority claimed from GB939301251A external-priority patent/GB9301251D0/en
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE69332541D1 publication Critical patent/DE69332541D1/de
Application granted granted Critical
Publication of DE69332541T2 publication Critical patent/DE69332541T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69332541T 1992-07-08 1993-07-08 Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie Expired - Fee Related DE69332541T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929214489A GB9214489D0 (en) 1992-07-08 1992-07-08 Pharmaceutical compositions and uses therefor
GB939301251A GB9301251D0 (en) 1993-01-22 1993-01-22 Pharmaceutical compositions and use therefor
PCT/EP1993/001790 WO1994001123A1 (en) 1992-07-08 1993-07-08 Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder

Publications (2)

Publication Number Publication Date
DE69332541D1 DE69332541D1 (de) 2003-01-16
DE69332541T2 true DE69332541T2 (de) 2003-04-17

Family

ID=26301225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332541T Expired - Fee Related DE69332541T2 (de) 1992-07-08 1993-07-08 Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie

Country Status (13)

Country Link
US (1) US5925344A (de)
EP (1) EP0651648B1 (de)
JP (1) JP3845112B2 (de)
AT (1) ATE228848T1 (de)
AU (1) AU674864B2 (de)
CA (1) CA2139353C (de)
DE (1) DE69332541T2 (de)
DK (1) DK0651648T3 (de)
ES (1) ES2183814T3 (de)
IL (1) IL106272A (de)
MX (1) MX9304075A (de)
PT (1) PT651648E (de)
WO (1) WO1994001123A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506016A (ja) * 1999-02-19 2003-02-18 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 動脈壁破裂障害のための診断剤および治療剤
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
WO2002015882A1 (en) * 2000-08-24 2002-02-28 Lytone Enterprise, Inc. Delayed release compositions and combinations
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
WO2011047346A1 (en) * 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2477530C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к интерлейкину-6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
JPH0372429A (ja) * 1988-10-07 1991-03-27 Chugai Pharmaceut Co Ltd 血小板減少症の治療剤
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5188828A (en) * 1990-11-08 1993-02-23 Brigham And Women's Hospital Interleukin-6 to stimulate erythropoietin production
WO1992008483A1 (en) * 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
WO1993006840A1 (fr) * 1991-10-09 1993-04-15 Toray Industries, Inc. Medicament de prevention et de traitement de la tendance a l'hemorragie

Also Published As

Publication number Publication date
DE69332541D1 (de) 2003-01-16
EP0651648B1 (de) 2002-12-04
JP3845112B2 (ja) 2006-11-15
IL106272A0 (en) 1993-11-15
JPH08502028A (ja) 1996-03-05
CA2139353A1 (en) 1994-01-20
DK0651648T3 (da) 2003-01-06
CA2139353C (en) 2006-11-07
ATE228848T1 (de) 2002-12-15
IL106272A (en) 1999-01-26
ES2183814T3 (es) 2003-04-01
WO1994001123A1 (en) 1994-01-20
US5925344A (en) 1999-07-20
MX9304075A (es) 1994-04-29
PT651648E (pt) 2003-04-30
EP0651648A1 (de) 1995-05-10
AU4566493A (en) 1994-01-31
AU674864B2 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
PT1011632E (pt) Composicao farmaceutica para o tratamento de dismenorreia e parto prematuro
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
DE69332541T2 (de) Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie
DE69316013T2 (de) Verwendung von phosphinate zur behandlung der osteoporose
DK0688226T3 (da) Proteinpræparat til forebyggelse og terapi af periodontitis eller andre bakterielle patologier i mundhulen
DE69231036T2 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
PT706395E (pt) Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo
DE69023006T2 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69330465T2 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
SE9303068D0 (sv) New use
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
ATA57894A (de) Mittel zur behandlung von osteoporose
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH

8339 Ceased/non-payment of the annual fee